Evidence map›Paper›PMID 28424415›Full record

ArticleOncotarget2017

Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients.

Thomas Sau-Yan Chan, Yuh-Shan Lee, Ilaria Del Giudice, Marilisa Marinelli, Caterina Ilari, Luciana Cafforio, Anna Guarini, Daryl Tan, Colin Phipps, Yeow-Tee Goh and 12 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 4 countries.

Thomas Sau-Yan ChanDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Yuh-Shan LeeDepartment of Haematology, Singapore General Hospital, Outram, Singapore.
Ilaria Del GiudiceDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Marilisa MarinelliDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Caterina IlariDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Luciana CafforioDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Anna GuariniDepartment of Molecular Medicine, Sapienza University, Rome, Italy.
Daryl TanDepartment of Haematology, Singapore General Hospital, Outram, Singapore.
Colin PhippsDepartment of Haematology, Singapore General Hospital, Outram, Singapore.
Yeow-Tee GohDepartment of Haematology, Singapore General Hospital, Outram, Singapore.
William HwangDepartment of Haematology, Singapore General Hospital, Outram, Singapore.
Allan Zhi-Kai GohDepartment of Haematology, Singapore General Hospital, Outram, Singapore.
Lisa Lai-Ping SiuDepartment of Pathology, Queen Elizabeth Hospital, Hong Kong, China.
Saliangi WuDepartment of Medicine, Queen Elizabeth Hospital, Hong Kong, China.
Chun-Yin HaDepartment of Medicine, Tuen Mun Hospital, Hong Kong, China.
Shek-Ying LinDepartment of Medicine, United Christian Hospital, Hong Kong, China.
Chi-Hang KwokDepartment of Medicine, Princess Margaret Hospital, Hong Kong, China.
Chi-Kuen LauDepartment of Medicine, Tseung Kwan O Hospital, Hong Kong, China.
Kit-Fai WongDepartment of Pathology, Queen Elizabeth Hospital, Hong Kong, China.
Robin FoàDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Yok-Lam KwongDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Eric TseDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Singapore General Hospital · SGSapienza University of Rome · ITQueen Elizabeth Hospital · CNQueen Mary Hospital · CNTseung Kwan O Hospital · CNTuen Mun Hospital · CNUnited Christian Hospital · CNUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukaemia (CLL) is uncommon in Chinese population and its biology, genetics and treatment outcome in Chinese patients have not been comprehensively investigated. In this study, we studied the clinicopathological features and outcome of 212 Chinese patients with newly diagnosed CLL in Hong Kong and Singapore. The median age at diagnosis was 64 years. The majority of patients presented with early-stage disease (Binet stage A, 56.1%). Del(13)(q14) was the most frequent abnormality (41.7%) detected by fluorescence in situ hybridization (FISH) analysis. Del(17p) and TP53 gene mutations were detected in 7.8% and 8.2% of patients, respectively. MYD88 mutations were found at a higher frequency (11.5%) than expected. CLL with unmutated variable region of the immunoglobulin heavy chain genes (IGHV) occurred in only 31.2% of cases, and was associated with advanced-stage disease (p <0.01) and adverse FISH abnormalities (p<0.01). With a median follow-up of 39 months, the median overall survival (OS) was 108 months. The presence of del(17p) or TP53 mutations was associated with a significantly shorter time to first treatment and an inferior OS (p <0.01). Unmutated IGHV was also associated with a significantly shorter time to treatment (p <0.01). Among patients who required treatment, the median OS and progression-free survival (PFS) were 107 and 23 months, respectively. The presence of del(17p) was associated with a significantly inferior OS and PFS (p <0.01). In summary, Chinese CLL patients had similar genetic aberrations at diagnosis compared with those of Western populations. FISH abnormalities are major factors affecting outcome.

Indexed as

AdultAgedAged, 80 and overAsian PeopleFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedTreatment OutcomeChinesechronic lymphocytic leukaemiaclinical outcomespathological characteristicsprognostication

Identifiers

PMID28424415
PMCPMC5421943
OpenAlexW2592506294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.